How long does it take to develop resistance to trametinib?

Trametinib is a kinase inhibitor used as a single agent for the treatment ofBRAF inhibitor therapy - treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations detected by an FDA-approved test. When used in combination with dabrafenib, it is indicated for the treatment of patients with unresectable or metastatic melanoma, the treatment of patients with metastatic non-small cell lung cancer (NSCLC), and the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC).

All drugs will develop resistance. The time for trametinib to develop resistance varies from person to person. According to clinical data, when trametinib is used as a single drug, the time to develop resistance will be faster, about half a year to one year. If trametinib is combined with dabrafenib, it will take longer to develop resistance and will not develop in the short term.

The recommended dose of trametinib for adult patients is 2 mg orally once daily. The recommended dose of trametinib in pediatric patients is based on body weight and should be taken at least 1 hour before or 2 hours after a meal. Trametinib DMSO is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl], and a compound (1:1) with 1,1'-sulfinylbis[methane]. Its molecular formula is C26H23 Fin 5O4C2H6OS and its molecular weight is 693.53 g/mol. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0